SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
ghmm
To: ghmm who wrote (3954)10/17/2015 10:32:14 PM
From: jaybe1 Recommendation  Read Replies (1) of 4474
 
I think this could be huge for pona. I've been tracking this trial for a year or so and I think they used 150mg, half of the approved frontline CML dose. Since we know nilo crosses the BBB at 5-6% of plasma concentrations and pona crosses the BBB at over 200% of plasma concentrations (see pona patent for PD/AD), it could be that very low doses of pona, 5-10mg, would be effective. First order of business is to demonstrate a 15mg dose in CML has very few side effects and no SAE's. This data will come with the OPTIC trial and could be available at ASH 2016. Ariad would definitely partner a non-oncology indication, but with 3M patients in the developed world any potential royalty would still be Ariad's biggest revenue generator by far.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News